Showing results (2771-2780 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|June 11, 2003
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinomaRobert J Motzer, Robert Amato, Mary Todd, et al.Investigational New Drugs|June 11, 2003
Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemiaDawn E Colburn, Deborah A Thomas, Francis J GilesInvestigational New Drugs|November 9, 2010
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapiesFrançois Ghiringhelli, Julie Vincent, Boris Guiu, et al.Investigational New Drugs|January 15, 2011
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposureChanghoon Yoo, Min-Hee Ryu, Baek-Yeol Ryoo, et al.Investigational New Drugs|December 25, 2010
The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stressKaustuv Sahoo, Mikhail G Dozmorov, Shrikant Anant, et al.Investigational New Drugs|October 7, 2010
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trialsStephane Ederhy, Christophe Massard, Ghislaine Dufaitre, et al.Investigational New Drugs|October 13, 2010
A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosisShama Moktan, Claudia Ryppa, Felix Kratz, et al.Investigational New Drugs|October 23, 2010
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialTianhong Li, Scott D Christensen, Paul H Frankel, et al.Investigational New Drugs|December 22, 2010
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidinesKohei Shitara, Satoshi Yuki, Motoki Yoshida, et al.Investigational New Drugs|December 17, 2010
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effectMichael Dickinson, Ricky W Johnstone, H Miles PrincePageof 372